Continuous intragastric delivery of fenoldopam: relationship between plasma concentration and effects on renal function.
1. The pharmacodynamics of the dopamine DA1 agonist fenoldopam were examined in six healthy male volunteers after constant intragastric infusions of fenoldopam at dosages of 0, 10, 25, 50 and 75 mg h-1 for 6 h. 2. Hourly p-aminohippurate (PAH) clearance was used to assess fenoldopam induced renal plasma flow changes. Marked dose-related increases in renal plasma flow were noted with a maximal increase of 65% over baseline values of 711 ml min-1 being seen at the 75 mg h-1 rate. No changes in sodium excretion and glomerular filtration rate were observed. 3. Mean steady-state fenoldopam plasma concentrations were related to mean PAH clearance based on an Emax model (r = 0.996) with an Emax of 1350 ml min-1 and an EC50 of 6.2 ng ml-1. 4. Mean steady-state plasma concentrations of fenoldopam-7-sulphate and fenoldopam-8-sulphate failed to increase with dose but were linearly correlated to mean PAH changes (r = 0.998, r = 0.981 respectively). 5. These results support the concept of extending fenoldopam's duration of action through the development of an oral sustained delivery system.
D000328:Adult; D001552:Benzazepines / Q000008:administration & dosage* / Q000097:blood / Q000494:pharmacology; D018818:Fenoldopam; D005919:Glomerular Filtration Rate; D006801:Humans; D007441:Intubation, Gastrointestinal; D007668:Kidney / Q000187:drug effects*; D008297:Male; D012079:Renal Circulation / Q000187:drug effects; D012964:Sodium / Q000652:urine; D013431:Sulfates / Q000652:urine; D010130:p-Aminohippuric Acid / Q000652:urine
D001552:Benzazepines; D013431:Sulfates; D012964:Sodium; D018818:Fenoldopam; D010130:p-Aminohippuric Acid